Latest news with #financing
Finextra
40 minutes ago
- Business
- Finextra
World Bank calls for "radical" restructuring of national debt reporting in new report
The World Bank released a report outlining how countries should redefine how they disclose debt due to more complexity in the current financing environment. 0 This content has been selected, created and edited by the Finextra editorial team based upon its relevance and interest to our community. The Radical Debt Transparency report found that private placements, central bank swaps, and collaterised transactions have complicated the reporting process. As a result, while the proportion of low-income countries publishing debt data has increased from under 60% to over 75% since 2020, only 25% have reported loan-level data on newly contracted debt. The report also found that domestically-issued debt is on the rise, but disclosures are not accurate. Furthermore, countries are also using confident debt restructurings with certain creditors which withholds essential data. World Bank's senior managing director Axel van Trotsenburg stated: 'Recent cases of unreported debt have highlighted the vicious cycle that a lack of transparency can set off. When hidden debt surfaces, financing dries up and terms worsen. Countries turn to opaque, collateralized deals. Radical debt transparency, which makes timely and reliable information accessible, is fundamental to break the cycle.' The report urges debtor and creditor countries to reform their transparency practices and issue mandates to ensure transparency in loan contracts and disclosures of lending terms. The report also suggests that there should be more frequent audits and better national oversight, published debt restructuring terms, and full participation from creditors in debt reconciliation processes. The World Bank is currently working to expand their global Debtor Reporting System to ensure that quality data is being shared and utilised. Pablo Saavedra, the World Bank's vice president for prosperity, commented: 'Debt transparency is not just a technical issue—it's a strategic public policy that that builds trust, reduces borrowing costs, and attracts investment. Radical debt transparency not only supports debt sustainability but also unlocks private sector investment to drive job creation.'
Bloomberg
7 hours ago
- Business
- Bloomberg
Apollo Nears Funding Deal of Up to £5 Billion for EDF's Hinkley
Save Apollo Global Management Inc. is nearing an agreement with Electricite de France SA to provide as much as £5 billion ($6.7 billion) of financing for the Hinkley Point C nuclear power plant in the UK. While the alternative asset manager previously considered providing a complex mix of equity and debt, the latest talks are mostly focused on conventional long-term loans, people with knowledge of the matter said, asking not to be identified because the deliberations are private.
Yahoo
9 hours ago
- Business
- Yahoo
BIOVAXYS ANNOUNCES AMENDED LIFE OFFERING
// NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES // VANCOUVER, BC, June 20, 2025 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") announces that it has amended the terms of its brokered private placement LIFE financing (the "Offering") previously announced on May 30, 2025, and filed an amended offering document (the "Amended Offering Document"). The Amended Offering Document updates the exercise price of the common share purchase warrant that forms part of the units ("Units") being offered by the Company from a post-consolidation exercise price of $0.60 to a post-consolidation exercise price of $0.50. As previously announced, the Company intends to consolidate the common shares of the Company (the "Common Shares") on the basis of ten (10) pre-consolidation Common Shares for one (1) post-consolidation Common Share (the "Consolidation"), and complete a concurrent Offering consisting of a minimum of 5,714,285 Units at a post-Consolidation price of $0.35 per Unit for minimum gross proceeds of $2,000,000 and a maximum of 8,571,428 Units at a post-Consolidation price of $0.35 per Unit for maximum gross proceeds of up to $3,000,000. Each Unit will consist of one (1) post-Consolidation common share in the capital of the Company (each, a "Post-Consolidation Common Share") and one (1) Post-Consolidation Common Share purchase warrant (each, a "Post-Consolidation Warrant"). Each Post-Consolidation Warrant will entitle the holder thereof to purchase one Post-Consolidation Common Share at a post-Consolidation price of $0.50 for a period of 36 months from the closing date of the Offering. Closing of the Offering is anticipated to occur on or about June 30, 2025, or such other date as the Company may agree upon provided such date is on or before July 14, 2025. Closing of the Offering is subject to the satisfaction of certain conditions, including, but not limited to, acceptance by the CSE. The Company intends to use the net proceeds raised from the Offering for research and development, general corporate purposes and working capital. Subject to compliance with applicable regulatory requirements and in accordance with National Instrument 45-106 – Prospectus Exemptions ("NI 45-106"), the Units issuable under the Offering will be offered for sale to purchasers in all provinces and territories of Canada, except Quebec, pursuant to the listed issuer financing exemption ("LIFE") under Part 5A of NI 45-106. The securities to be issued pursuant to the sale of the Units under the Offering will not be subject to resale restrictions in accordance with applicable Canadian securities laws. There is an Amended Offering Document dated June 18, 2025, related to the Offering that can be accessed under the Company's profile at and on the Company's website at Prospective investors should read this offering document before making an investment decision. This news release does not constitute an offer to sell or a solicitation of an offer to buy of any securities in the United States, or in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws, and may not be offered or sold within the United States except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities laws or pursuant to available exemptions therefrom. About BioVaxys Technology Corp. BioVaxys Technology Corp. ( a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it's HapTenix© tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization for food allergy, and other immunological diseases. Through a differentiated mechanism of action, the DPX™ platform delivers instruction to the immune system to generate a specific, robust, and persistent immune response. The Company's clinical stage pipeline includes maveropepimut-S (MVP-S), based on the DPX™ platform, and in Phase IIB clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant Ovarian Cancer. MVP-S delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers, and also delivers an innate immune activator and a universal CD4 T cell helper peptide. MVP-S has been well tolerated and has demonstrated defined clinical benefit in multiple cancer indications as well as the activation of a targeted and sustained, survivin-specific anti-tumor immune response. BioVaxys is also developing DPX™+SurMAGE, a dual-targeted immunotherapy combining antigenic peptides for both the survivin and MAGE-A9 cancer proteins to elicit immune responses to these two distinct cancer antigens simultaneously, DPX™-RSV for Respiratory Syncytial Virus, DPX+rPA for peanut allergy prophylaxis, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix© 'neoantigen' tumor cell construct platform for refractive late-stage ovarian cancer. BioVaxys common shares are listed on the CSE under the stock symbol "BIOV" and trade on the Frankfurt Bourse (FRA: 5LB) and in the U.S. on the OTC Markets (OTCQB marketplace). For more information, visit and connect with us on X and LinkedIn. ON BEHALF OF THE BOARDSigned "James Passin" James Passin, Chief Executive OfficerPhone: +1 740 358 0555 Cautionary Statements on Forward Looking Information This news release includes certain "forward-looking information" and "forward-looking statements" (collectively "forward-looking statements") within the meaning of applicable securities legislation. All statements, other than statements of historical fact, included herein, without limitation, statements relating to the future operating or financial performance of the Company, are forward-looking statements. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "estimates", "potential", "possible", and similar expressions, or statements that events, conditions, or results "will", "may", "could", or "should" occur or be achieved. Forward-looking statements in this news release relate to, among other things, the proposed Consolidation, including the ratio thereof and timing thereof, and the Offering, including the size and use of proceeds, and the timing and ability of the Company to close the Offering, including obtaining approval of the Offering from the CSE. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those expressed or implied in such forward-looking statements. Forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates, primarily the assumption that BioVaxys will be successful in developing and testing vaccines, that, while considered reasonable by BioVaxys, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies including, primarily but without limitation, the risk that BioVaxys' vaccines will not prove to be effective and/ or will not receive the required regulatory approvals. With regards to BioVaxys' business, there are a number of risks that could affect the development of its biotechnology products, including, without limitation, the need for additional capital to fund clinical trials, its lack of operating history, uncertainty about whether its products will complete the long, complex and expensive clinical trial and regulatory approval process for approval of new drugs necessary for marketing approval, uncertainty about whether its autologous cell vaccine immunotherapy can be developed to produce safe and effective products and, if so, whether its vaccine products will be commercially accepted and profitable, the expenses, delays and uncertainties and complications typically encountered by development stage biopharmaceutical businesses, financial and development obligations under license arrangements in order to protect its rights to its products and technologies, obtaining and protecting new intellectual property rights and avoiding infringement to third parties and their dependence on manufacturing by third parties. Many factors, both known and unknown, could cause actual results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements and the parties have made assumptions and estimates based on or related to many of these factors. Such factors include, without limitation, the ability of the Company to complete the Consolidation and the Offering on the terms proposed or at all, and the ability to obtain necessary approvals, including the approval of the CSE. BioVaxys does not assume any obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by applicable securities laws. The CSE has not reviewed, approved nor disapproved the contents of this news release and does not accept responsibility for the adequacy or accuracy of this news release. Logo: View original content: SOURCE BioVaxys Technology Corp. View original content: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19 hours ago
- Business
- Yahoo
SYF Joins Forces With Payzer to Streamline Home Improvement Financing
A leading consumer financing player, Synchrony Financial SYF, recently collaborated with Payzer to develop an integrated digital solution for residential contractors. The initiative is designed to bring SYF's financing options directly into Payzer's field service management solution to increase efficiency, provide more flexibility and enhance customer satisfaction. With Synchrony's impressive lineup of 33 financing promotions now available directly through the Payzer platform, contractors can easily offer financing options during estimates, manage pre-qualifications and get instant credit decisions — all from one smooth interface. This streamlined process can speed up payment timelines and even result in increased average transaction values. With increasing consumer interest in Buy Now Pay Later (BNPL) options and home equity solutions, SYF and Payzer's collaboration is ideally suited to meet consumers' evolving financial wants. This partnership is a strategic move and aligns with the companies' missions. Synchrony is growing its presence in the high-potential home service business, while Payzer adds value to its proposition by making it easier to pay. This collaboration could also boost market reach for both companies, especially among mid-sized contractors who may not have access to advanced financial tools. It also empowers contractors and simplifies financial choices for homemakers. Synchrony emphasizes partnerships and acquisitions to drive business growth, enhances digital capabilities and focuses on diversified offerings. SYF extended its longstanding partnerships with American Eagle Outfitters and Ashley in April. Over the past year, Synchrony shares have gained 36.8% compared with the industry's growth of 9.5%. Image Source: Zacks Investment Research SYF currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader finance space are Pagaya Technologies Ltd. PGY, Heritage Insurance Holdings Inc. HRTG and Virtu Financial Inc. VIRT, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today's Zacks #1 Rank stocks here. The Zacks Consensus Estimate for Pagaya Technologies' current-year earnings of $2.45 per share has witnessed two upward revisions in the past 60 days against none in the opposite direction. Pagaya Technologies beat earnings estimates in two of the trailing four quarters and missed twice, with the average surprise being 12.9%. The consensus estimate for current-year revenues is pegged at $1.2 billion, implying 19.9% year-over-year growth. The Zacks Consensus Estimate for Heritage Insurance's current-year earnings of $3.25 per share has witnessed two upward revisions in the past 60 days against no movement in the opposite direction. Heritage Insurance beat earnings estimates in each of the trailing four quarters, with the average surprise being 363.2%. The consensus estimate for current-year revenues is pegged at $854.9 million, calling for 4.6% year-over-year growth. The Zacks Consensus Estimate for Virtu Financial's current-year earnings is pegged at $3.97 per share, implying 11.8% year-over-year growth. In the past 60 days, Virtu Financial has witnessed five upward estimate revisions against none in the opposite direction. The consensus mark for the current-year revenues is pegged at $1.7 billion, indicating 5.2% year-over-year growth. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Synchrony Financial (SYF) : Free Stock Analysis Report Heritage Insurance Holdings, Inc. (HRTG) : Free Stock Analysis Report Virtu Financial, Inc. (VIRT) : Free Stock Analysis Report Pagaya Technologies Ltd. (PGY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
a day ago
- Business
- Yahoo
Ísfélag hf. participation in financing of Austur Holding AS in connection with Kaldvik AS share capital increase
Ísfélag hf. (the 'Company'), which holds a 29.3% stake in Austur Holding AS ('Austur'), hereby announces its participation in the financing of Austur in relation to Austur's subscription in a share capital increase of Kaldvik AS, following the approval of an extraordinary general meeting of Kaldvik AS on 19 June 2025. Kaldvik AS, listed on Nasdaq First North Growth Market and Euronext Growth in Oslo, announced on 5 June 2025 the results of a private placement of 38,011,500 new shares for a total subscription amount of NOK 532 million, equivalent to approximately EUR 46.2 million. Austur was allocated 27,045,027 shares, representing approximately 71.2% of the total allocation, for a total subscription amount of NOK 378.6 million, or approximately EUR 33 million. The allocation of new shares was i.a. subject to approval by the extraordinary general meeting of Kaldvik AS. Furthermore, following the private placement, the purchase by Austur of an additional 860,000 shares in Kaldvik AS was announced on 10 June 2025. Following shareholder approval of the share capital increase in Kaldvik AS on 19 June 2025, Austur is obliged to settle its allocated portion of the new shares pursuant to the private placement. In accordance with a financing agreement between Austur and its shareholders, Ísfélag will provide financing in connection with the aforementioned transactions in the amount of NOK 341 million (approximately EUR 29.7 million), comprising an equity contribution and in the form of convertible shareholder loans. Following these transactions Austur shareholding in Kaldvik AS will be a 57.35% but was previously 54,06%. The investment forms part of the Company's strategy to diversify its revenue streams and to support the continued development of Kaldvik in to access your portfolio
